USA - engelska - NLM (National Library of Medicine)

cmp pharma, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral replacement is not possible, insufficient or contraindicated. potassium phosphates injection is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. limitations of use safety has not been established for parenteral nutrition in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risk of aluminum toxicity [see warnings and precautions (5.5), use in specific population (8.4) ]. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warnings and precautions (5.3) ] - hyperphosphatemia [see warnings and precautions (5.4) ] -

USA - engelska - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)] - severe renal impairment (egfr less than 30 ml/min/1.73m2 ) or end stage renal disease [see warning and precautions (5.3)] - hyperphosphatemia [see warning and precautions (5.4)] - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates inj

USA - engelska - NLM (National Library of Medicine)

amneal pharmaceuticals private limited - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)]. - hyperphosphatemia [see warning and precautions (5.4)]. - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] .  - severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see warning and precautions (5.3)] . risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk phosphorus is an essential mineral element. parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake. risk summary phosphorus and potassium are present in human milk. administration of the recommended dose of potassium phosphates injection is not expected to cause harm to a breastfed infant. there is no information on the effects of potassium phosphates on milk production. the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for potassium phosphates injection and any potential adverse effects on the breastfed child from potassium phosphates injection or from underlying maternal condition. safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. - for parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.6)] . in general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. it may be useful to monitor renal function during treatment [see use in specific populations (8.6)] . potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function [see warnings and precautions (5.3, 5.4, 5.5)] . potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see contraindications (4)] . in patients with moderate renal impairment (egfr ≥ 30 ml/min/1.73 m2 to < 60 ml/min/1.73 m2 ), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium and magnesium concentrations [see dosage and administration (2.2, 2.4)].

USA - engelska - NLM (National Library of Medicine)

american health packaging - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

USA - engelska - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

USA - engelska - NLM (National Library of Medicine)

carilion materials management - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. tm this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia. . see dosage and administration

Australien - engelska - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - potassium phosphate - dibasic; potassium phosphate - monobasic -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

glen gillard t/a wonder foods - dibasic potassium phosphate -

Kanada - engelska - Health Canada

fresenius kabi canada ltd - potassium phosphate monobasic; potassium phosphate dibasic - solution - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations

USA - engelska - NLM (National Library of Medicine)

seroyal usa - potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, dibasic 1 [hp_x] - indications for the temporary relief of fatigue, muscle aches and pains indications for the temporary relief of fatigue, muscle aches and pains directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.